Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

High attrition rates of novel anti-cancer drugs highlight the need for improved models to predict toxicity. Although polo-like kinase 1 (Plk1) inhibitors are attractive candidates for drug development, the role of Plk1 in primary cells remains widely unexplored. Therefore, we evaluated the utility o...

Descripción completa

Detalles Bibliográficos
Autores principales: Raab, Monika, Kappel, Sven, Krämer, Andrea, Sanhaji, Mourad, Matthess, Yves, Kurunci-Csacsko, Elisabeth, Calzada-Wack, Julia, Rathkolb, Birgit, Rozman, Jan, Adler, Thure, Busch, Dirk H., Esposito, Irene, Fuchs, Helmut, Gailus-Durner, Valérie, Klingenspor, Martin, Wolf, Eckhard, Sänger, Nicole, Prinz, Florian, Angelis, Martin Hrabě de, Seibler, Jost, Yuan, Juping, Bergmann, Martin, Knecht, Rainald, Kreft, Bertolt, Strebhardt, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144583/
https://www.ncbi.nlm.nih.gov/pubmed/21772266
http://dx.doi.org/10.1038/ncomms1395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144583/
https://www.ncbi.nlm.nih.gov/pubmed/21772266
http://dx.doi.org/10.1038/ncomms1395

Ejemplares similares